NCT02366468 - Study of Efficacy of Ranibizumab in Different Regimens in Patients With Diabetic Macula Edema | Biotech Hunter

Enrollment

135

Participants

Timeline

Start Date

February 23, 2015

Primary Completion Date

June 8, 2017

Study Completion Date

June 8, 2017

Conditions

Diabetic Retinopathy

Interventions

DRUG

ranibizumab 0.5 mg

intravitreal injection

Trial Locations (30)

12203

Novartis Investigative Site, Berlin

14169

Novartis Investigative Site, Berlin

17475

Novartis Investigative Site, Greifswald

20246

Novartis Investigative Site, Hamburg

23538

Novartis Investigative Site, Lübeck

35043

Novartis Investigative Site, Marburg

37075

Novartis Investigative Site, Göttingen

39108

Novartis Investigative Site, Magdeburg

40212

Novartis Investigative Site, Düsseldorf

40225

Novartis Investigative Site, Düsseldorf

48145

Novartis Investigative Site, Münster

48149

Novartis Investigative Site, Münster

48683

Novartis Investigative Site, Ahaus

50924

Novartis Investigative Site, Cologne

50935

Novartis Investigative Site, Cologne

53127

Novartis Investigative Site, Bonn

63768

Novartis Investigative Site, Hösbach

67063

Novartis Investigative Site, Ludwigshafen

70174

Novartis Investigative Site, Stuttgart

72076

Novartis Investigative Site, Tübingen

79106

Novartis Investigative Site, Freiburg I. Br

80333

Novartis Investigative Site, München

81675

Novartis Investigative Site, München

87435

Novartis Investigative Site, Kempten

89075

Novartis Investigative Site, Ulm

95444

Novartis Investigative Site, Bayreuth

97080

Novartis Investigative Site, Würzburg

01067

Novartis Investigative Site, Dresden

06114

Novartis Investigative Site, Halle

04103

Novartis Investigative Site, Leipzig